Eli Lilly and Company: Migraine Disorders trials

The registry lists 33 Migraine Disorders studies with Eli Lilly and Company as lead sponsor. 0 are open to participants now and 32 have results posted.

Early Phase 1 1Phase 1 8Phase 2 9Phase 3 12Phase 4 2No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic MigraineCompletedNCT05127486Phase 4Results posted
• A Study of LY3451838 in Participants With MigraineCompletedNCT04498910Phase 2Results posted
• A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With MigraineTerminatedNCT04396574Phase 3Results posted
• A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With MigraineTerminatedNCT04396236Phase 3Results posted
• A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP AntagonistCompletedNCT04294147Phase 4Results posted
• A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With MigraineCompletedNCT03988088Phase 1Results posted
• A Study of Galcanezumab (LY2951742) in Participants With Episodic MigraineCompletedNCT03963232Phase 3Results posted
• A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With MigraineCompletedNCT03962738Phase 2Results posted
• A Study of Lasmiditan (LY573144) Over Four Migraine AttacksCompletedNCT03670810Phase 3Results posted
• A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant MigraineCompletedNCT03559257Phase 3Results posted
• A Study of Lasmiditan in Participants With MigraineCompletedNCT03247790Phase 1Results posted
• Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy ParticipantsCompletedNCT03076970Phase 1Results posted
• Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic FunctionCompletedNCT03040479Phase 1Results posted
• The Effects of Lasmiditan on Simulated Driving Performance - Healthy ParticipantsCompletedNCT03012334Phase 1Results posted
• Study of Oral Lasmiditan in Participants With Normal and Impaired Renal FunctionCompletedNCT03009162Phase 1Results posted
• A Study of LY2951742 (Galcanezumab) in Japanese Participants With MigraineCompletedNCT02959190Phase 3Results posted
• A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic MigraineCompletedNCT02959177Phase 2Results posted
• Biomarker Study in Participants With MigraineCompletedNCT02766517Early Phase 1Results posted
• A Safety Study of Galcanezumab in Participants With Migraine, With or Without AuraCompletedNCT02614287Phase 3Results posted
• Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 StudyCompletedNCT02614196Phase 3Results posted
• Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 StudyCompletedNCT02614183Phase 3Results posted
• Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of MigraineCompletedNCT02605174Phase 3Results posted
• An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of MigraineCompletedNCT02565186Phase 3Results posted
• Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:CompletedNCT02439320Phase 3Results posted
• A Study of Galcanezumab (LY2951742) in Participants With Migraine HeadacheCompletedNCT02163993Phase 2Results posted
• A Study of LY2951742 in Healthy Japanese and Caucasian ParticipantsCompletedNCT02104765Phase 1Results posted
• A Study of LY2951742 in Participants With MigraineCompletedNCT01625988Phase 2Results posted
• A Study of LY2951742 in Healthy VolunteersCompletedNCT01337596Phase 1Results posted
• A Study in Migraine PreventionTerminatedNCT01184508Phase 2Results posted
• Dose-ranging Study of Oral COL-144 in Acute Migraine TreatmentCompletedNCT00883051Phase 2Results posted
• Study in Participants With Acute Migraines HeadachesTerminatedNCT00804973Phase 2Results posted
• A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of MigraineCompletedNCT00384774Phase 2Results posted
• A Study of the Effect of a Disease-Specific Migraine Smart Phone Application (App) on Participant CareCompletedNCT03559088Not applicable